Centre National De La Recherche Scientifique

Universitè De Montpellier

Institut Curie

Abivax

Abivax Sa

Noelie Campos

Jamal Tazi

Didier Scherrer

Romain Najman

Florence Mahuteau

Aude Garcel

Pauline Fornarelli

Audrey Vautrin

Florence Mahuteau-Betzer

Pierre Roux

Gilles Gadea

Julien Santo

Carsten Brock

Nathalie Cahuzac

The present invention relates to a quinoline derivative of formula (I) or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored. The present invention further relates to a quinoline derivative of formula (I) as defined in claim, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, for which an ineffectiveness or a decline in a prior anti-retroviral treatment effectiveness has been stated and to a quinoline derivative of formula (I) as defined above, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, wherein the patient is infected by a drug-resistant viral strain, and more particularly by a drug-resistant HIV strain. 

Quinoline derivatives for use in the treatment or prevention of viral infection

The present invention relates to a method for screening a compound useful for treating or preventing a viral infection or a virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to promote the interaction between CBP20 and CBP80 in a sample, and b) selecting the candidate compound that is determined to promote said interaction at step a). The present invention further relates to a method for screening a compound useful for treating or preventing a viral infection or virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to interact with CBP20 or CBP80 in a sample, and b) selecting the candidate compound that is determined to interact with CBP20 or CBP80 at step a).

Methods for screening compounds for treating or preventing a viral infection or a virus-related condition

The present invention relates to a quinoline derivative of formula (1) or one of its pharmaceutically acceptable salts. The present invention further relates to said quinoline derivative for medicament and for use in the treatment or prevention of a viral or retroviral infection and in particular AIDS or an AIDS-related condition or Human Immunodeficiency virus (HIV). The present invention also relates to a pharmaceutical composition comprising said quinoline derivative and to the process for preparing it as to a novel intermediate compound. 

Quinoline derivative for use in the treatment and prevention of viral infections

The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where:

Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging

A compound having the following formula or a pharmaceutically acceptable salt thereof: where:

Compounds useful for treating AIDS

Compounds useful for treating aids

The present invention relates to compound Formula (I) wherein: Formula (II) means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a CN group, a hydroxyl group, a COORgroup, a (C-C)fluoroalkyl group, a (C-C)fluoroalkoxy group, a NOgroup, a NRRgroup, a (C-C)alkoxy group, a phenoxy group and a (C-C)alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group, n is 1, 2 or 3, n is 1 or 2, R is a hydrogen atom, a halogen atom or a group chosen among a (C-C)alkyl group, a hydroxyl group, a COORgroup, a NOgroup, a NRRgroup, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C-C)fluoroalkyl group, a (C-C)alkoxy group and a CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C, for use as an agent for preventing, inhibiting or treating AIDS. Some of said compounds are new and also form part of the invention.

Growing community of inventors

Le Cres, France

Noelie Campos